SequelSEC

Tango Therapeutics, Inc. TNGX

Pharmaceutical Preparations · CIK 0001819133 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$53.81M
Fiscal year ended 2026-06-30
Operating income
-$136.35M
Fiscal year ended 2026-06-30
Free cash flow
-$144.25M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$528.40MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$3.70Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue8.5×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity1.5×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Current ratio16.32x92th
Revenue YoY growth48.3%75th
FCF margin-224.3%40th
SBC / revenue42.4%59th
R&D / revenue211.9%53th
CapEx / revenue1.7%48th
Operating margin-178.4%52th
Net margin-162.9%51th

Tango Therapeutics, Inc. (TNGX) reported revenue of $53.81M and net income of -$123.72M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Tango Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Tango Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$53.81M
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$136.35M
Net income-$123.72M
Research & development$133.65M
Weighted-average diluted sharesUnavailable
Pretax income-$123.78M
Income tax expense-$63.00K
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$56.51M
Selling & marketingUnavailable

Balance

Tango Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$345.56M
Total assets$1.07B
Current assets$1.03B
Total liabilities$49.35M
Current liabilities$20.30M
Total equity incl. NCI$1.02B
Temporary (mezzanine) equity$0
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$1.81M

Cash flow

Tango Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$143.90M
Capital expenditures$351.00K
Investing cash flow-$524.58M
Financing cash flow$974.33M
Net change in cash$305.86M
Stock-based compensation$40.29M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

Tango Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$144.25M
Gross marginUnavailable
Operating margin-253.4%
FCF margin-268.1%
SBC / revenue74.9%
Current ratio50.82x
Revenue YoY growth121.5%
Net margin-229.9%
R&D / revenue248.4%
CapEx / revenue0.7%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open TNGX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-11View SEC filing
10-Q · Filed 2026-05-13View SEC filing
10-K · Filed 2026-03-05View SEC filing
10-Q · Filed 2025-11-04View SEC filing
10-Q · Filed 2025-08-05View SEC filing
10-Q · Filed 2025-05-12View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.